文献速递类风湿关节炎

类风湿关节炎三联疗法与依那西普的不良事件差异

Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

本研究基于Rheumatoid Arthritis Comparison of Active Therapies Trial,纳入353例MTX应答不佳的RA患者,随机接受三联疗法(T:MTX+SSZ+HCQ)或依那西普(E)+MTX。结果显示E组感染性非严重AE发生率更高(IRR=1.56),而胃肠道非严重AE更低(IRR=0.62),两组严重AE无显著差异。

要点

  • 依那西普组感染性非严重不良事件风险高于三联疗法(IRR=1.56)。
  • 三联疗法组胃肠道非严重不良事件风险高于依那西普组(IRR=0.62)。
  • 两组感染性及胃肠道严重不良事件发生率无统计学显著差异。

核心结论

  • 对于MTX应答不佳的RA患者,依那西普联合MTX与三联疗法在感染性和胃肠道不良事件风险上存在差异。

研究设计与样本

  • 研究为Rheumatoid Arthritis Comparison of Active Therapies Trial,纳入353例MTX应答不佳的RA患者,随机分为三联疗法组(n=178)和依那西普组(n=175)。
  • 88例患者在24周时按方案切换至另一治疗,不良事件报告至干预期后48周及4周。
  • 采用广义线性模型估计两种疗法间不良事件的发生率比(IRR)。

主要发现

  • 依那西普组感染性非严重不良事件发生率高于三联疗法组(IRR=1.56,95%CI:1.11,2.19)。
  • 依那西普组感染性严重不良事件12例(6.9%),三联疗法组4例(2.2%),P=0.19。
  • 肺炎是两组最常见的感染性严重不良事件(依那西普组6例(3.4%),三联疗法组2例(1.1%))。
  • 依那西普组胃肠道非严重不良事件发生率低于三联疗法组(IRR=0.62,95%CI:0.40,0.94)。
  • 最常见的胃肠道严重不良事件为胃肠道出血,依那西普组发生3例(1.7%)。

关键数值与推荐

  • 感染性非严重不良事件:依那西普组 vs 三联疗法组 IRR=1.56(95%CI:1.11,2.19)。
  • 胃肠道非严重不良事件:依那西普组 vs 三联疗法组 IRR=0.62(95%CI:0.40,0.94)。
  • 感染性严重不良事件:依那西普组12例(6.9%) vs 三联疗法组4例(2.2%),P=0.19。

临床怎么用

  • 对于MTX应答不佳的RA患者,选择依那西普联合MTX时需关注感染性非严重不良事件风险。
  • 选择三联疗法时需关注胃肠道非严重不良事件风险。
  • 两种方案疗效相当,不良事件谱不同,临床决策应结合患者个体风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The main aim of this study was to examine the differences between triple therapy (T: SSZ and HCQ added to MTX) and etanercept (E) added to MTX with regard to the infectious and gastrointestinal (GI) adverse events (AEs) reported in The Rheumatoid Arthritis Comparison of Active Therapies Trial. METHODS: The patients were 353 RA MTX incomplete responders who were randomized to T (n = 178) or E (n = 175). Of these, 88 patients were switched to the alternative treatment from the initial treatment (E or T) at 24 weeks per protocol. Infectious and GI serious AEs (SAEs) and non-serious AEs (NAEs) were reported during 48 and 4 weeks after the intervention period. Generalized linear models were used to estimate the incidence rate ratios (IRRs) of AEs between the two therapies. RESULTS: Patients on E therapy were more likely to have infectious NAEs (IRR = 1.56, 95% CI: 1.11, 2.19). There was a greater number of infectious SAEs that occurred when patients received E than T therapy [12 E (6.9%) vs 4 T (2.2%), P = 0.19]. Pneumonia was the most common infectious SAE for both treatments [6 E (3.4%) and 2 T (1.1%)]. Conversely, patients who were on E were less likely to have GI NAEs than those on T therapy (IRR = 0.62, 95% CI: 0.40, 0.94). The most common GI SAE reported was GI haemorrhage, which occurred among three patients on E (1.7%). CONCLUSION: This study provides evidence of different likelihoods of infectious and GI AEs associated with two common, equally effective treatments for RA patients who have had incomplete responses to MTX. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov , NCT00405275.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Quach LT, Chang BH, Brophy MT, et al. Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. Rheumatology (Oxford). 2017. PMID: 27994091. doi:10.1093/rheumatology/kew412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。